UCB's Global Corporate Website
Welcome to UCB in the United States

Jun

01

Life with MG & What I Wish For Everyone Who is Diagnosed

May

27

My Commitment to the Newly Diagnosed and All People Living with Myasthenia Gravis

May

24

UCB’s Community Health Fund Applications are Open for Organizations Supporting the Mental Health of Young People and those Displaced Due to Conflict

May

23

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

May

23

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

May

20

Recognizing the Importance of Clinical Studies

Clinical studies are an essential part of biopharmaceutical research on the journey to discover, develop and deliver new solutions to people living with severe diseases. This Clinical Trial Awareness week, UCB thanks all of the participants in UCB studies and the dedicated researchers doing this important work.

May

17

Prioritizing Mental Health for our People, Patients, and Purpose

Mental health is top of mind at UCB as we work to prioritize the well-being of our people and the patients we serve. A core pillar of our sustainable business approach, we understand that delivering innovative solutions for patients begins with supporting the physical, mental, and social well-being of our employees, their families, and communities, now and in the future. This Mental Health Awareness Month, learn how we’re supporting mental wellness for our people, patients, and our purpose. 

May

12

Recognizing the Less Common, but Equally Burdensome, Forms of Arthritis During Arthritis Awareness Month

May

10

Recognizing our Rising Star and Luminary: Kerry Black and Brooke Fleming Recognized by the Healthcare Businesswomen’s Association

UCB congratulates Kerry Black, Head of Early Solutions U.S. Operations, and Brooke Fleming, Head of Omnichannel Marketing and Digital Enablement, for their recognition by the Healthcare Businesswomen's Association (HBA) as 2022 Luminary and Rising Star, respectively. 

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis